Abstract:BackgroundIn complex automated clinical laboratory Next Generation Sequencing (NGS) workflows, numerous opportunities exist for contamination events to occur. For oncology testing applications, detection of these events is crucial for accurate results reporting. A contamination detection module (MICon) using microhaplotype (MH) regions and an in-house designed analysis model was developed for use in a NGS assay for myeloid neoplasms (NGSHM) [1]. Variant detection for NGSHM has a validated analytical sensitivity of 2% variant allele frequency (VAF). Gross contamination events can potentially cause erroneous false positive variant detection whereas true low VAF mutations may be masked and evade detection. The following study was performed to evaluate MICon module performance on samples processed over the course of a year.MethodsMH regions contain highly conserved tandem single nucleotide polymorphisms (SNPs) with high global heterogeneity occurring within a 300-nucleotide span. From the work of Kidd et al [2], 27 MH regions covering 92 SNPs and spanning 16 chromosomes were selected for inclusion in the 47 gene NGSHM target-capture panel. Sequencing was performed on a NovaSeq 6000 and analyzed through an internal bioinformatics pipeline, which incorporates the MICon module. MICon uses a binary classification model incorporating VAFs from MH regions, number of MH genotypes, and the contamination estimation score from verifyBamID to compute a single value on a 0-100 scale. Scores <50 are classified as non-contaminated and scores ≥50 require further investigation.ResultsThe dataset was comprised of 10,990 samples. A total of 10,232 patient cases (93.1%) had non-contaminated MICon scores <50. Control replicates accounted for 261 samples (2.4%). There were 497 patient cases (4.5%) with MICon scores ≥50. Of the 497 patient cases, 137 (27.6%) had undergone hematopoietic stem cell transplantation (HSCT) and 114 (22.9%) contained gross chromosomal abnormalities, representing iatrogenic or tumor biological factors. An additional 135 (27.2%) of cases were contaminated from laboratory processing errors, 45 (9.1%) occurred due to chemistry failures during run processing, and 66 (13.2%) had an undetermined cause for a high score, representing laboratory-related and unknown factors. Overall, the 135 laboratory processing errors detected accounted for 1.3% of patient cases analyzed by the laboratory. These cases were repeated, and the non-contaminated results were accurately reported.ConclusionsHerein it was shown the implementation of MICon has improved patient safety over the course of a year. The 1.3% of patient cases identified as arising from laboratory processing errors were successfully reprocessed. While the overall rate of laboratory processing errors appears low, the absolute number can be significant in a high-volume test setting, despite reliance on highly automated processes. Value is added by MICon through identifying errors that could result in the release of inaccurate patient results. By detecting previously unrealized errors, MICon has become an invaluable asset to the NGSHM assay by enhancing patient laboratory testing safety. References :[1] Balan J, et al. MICon Contamination Detection Workflow for Next-Generation Sequencing Laboratories Using Microhaplotype Loci and Supervised Learning. J Mol Diagn . 2023;25(8):602-610. doi:10.1016/j.jmoldx.2023.05.001.[2] Kidd KK, et al. Selecting microhaplotypes optimized for different purposes. Electrophoresis . 2018;39(21):2815-2823. doi:10.1002/elps.201800092.

Evaluation of false positive and false negative errors in targeted next generation sequencing

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study

Analysis of error profiles in deep next-generation sequencing data

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

Detection of False-Positive Deletions from the Database of Genomic Variants

Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice

High efficiency error suppression for accurate detection of low-frequency variants

An Innovative Data Analysis Strategy For Accurate NGS Detection of Tumor mtDNA Mutations

Enhancing Clinical Applications by Evaluation of Sensitivity and Specificity in Whole Exome Sequencing

Effective quality management practices in routine clinical next-generation sequencing

A comprehensive assessment of Next-Generation Sequencing variants validation using a secondary technology.

Targeted Next-Generation Sequencing As a Comprehensive Test for Mendelian Diseases: a Cohort Diagnostic Study.

Comparison of exon-level copy number variants in CytoScan XON assay and next-generation sequencing in clinical samples

Next Generation Sequencing in Oncological Diagnostics: Hype or Hope?

Evaluation of Copy Number Variant Detection from Panel‐based Next‐generation Sequencing Data

Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy

Evaluation of next generation sequencing platforms for population targeted sequencing studies

B-232 One Year Post-Implementation Experience Using a Custom Designed DNA Contamination Detection Module for a Clinical Myeloid Neoplasm Next Generation Sequencing Assay

Application of Next-Generation Sequencing in the Detection of Low-Abundance Mutations.

Subjecting Appropriate Lung Adenocarcinoma Samples to Next‐generation Sequencing‐based Molecular Testing: Challenges and Possible Solutions